

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

CD4 MicroBeads, human

RRID:AB_2889919

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-045-101, RRID:AB_2889919

Antibody Information

URL: http://antibodyregistry.org/AB_2889919

Proper Citation: Miltenyi Biotec Cat# 130-045-101, RRID:AB_2889919

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: positive selection or depletion of CD4+ cells by direct magnetic labeling

Antibody Name: CD4 MicroBeads, human

Description: This monoclonal targets CD4

Target Organism: human

Antibody ID: AB_2889919

Vendor: Miltenyi Biotec

Catalog Number: 130-045-101

Record Creation Time: 20250819T210508+0000

Record Last Update: 20250819T214806+0000

Ratings and Alerts

No rating or validation information has been found for CD4 MicroBeads, human.

No alerts have been found for CD4 MicroBeads, human.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#).

Wang J, et al. (2026) EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. Cell.

Liao H, et al. (2026) Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma. Cancer communications (London, England), 46, 0014.

O'Reilly C, et al. (2026) LRRC15-CAR T Cells for the Treatment of Osteosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1557.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Bernasconi-Bisio F, et al. (2025) Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. Molecular therapy. Oncology, 33(1), 200949.

Libri AB, et al. (2025) Senataxin promotes recombination fidelity during antigen receptor gene diversification. Science signaling, 18(908), eadv8801.

Madorsky Rowdo FP, et al. (2025) Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition. Cancer research, 85(3), 551.

Wu Q, et al. (2024) Ferritin heavy chain supports stability and function of the regulatory T cell lineage. The EMBO journal, 43(8), 1445.

Reilly NA, et al. (2024) Oleic acid triggers metabolic rewiring of T cells poising them for T helper 9 differentiation. iScience, 27(4), 109496.

Talbot LJ, et al. (2024) Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(19), 4434.

Lozano-Rabella M, et al. (2023) Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(12), 2250.

Brown AC, et al. (2023) Comprehensive epigenomic profiling reveals the extent of disease-specific chromatin states and informs target discovery in ankylosing spondylitis. *Cell genomics*, 3(6), 100306.

Li H, et al. (2023) Exploring the dynamics and influencing factors of CD4 T cell activation using single-cell RNA-seq. *iScience*, 26(9), 107588.

Tredicine M, et al. (2022) A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis. *iScience*, 25(2), 103763.

Bonté PE, et al. (2022) Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. *Cell reports*, 39(10), 110916.